EMEA-001435-PIP02-16-M01

Key facts

Active substance
anifrolumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0239/2020
PIP number
EMEA-001435-PIP02-16-M01
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of Systemic Lupus Erythematosus (SLE)
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries
AstraZeneca AB

Tel.  +46 855259283
E-mail: paediatrics@astrazeneca.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating